US labeling for Eli Lilly and Company’s Alzheimer’s drug Kisunla (donanemab-azbt) allows for treatment cessation upon clearance of amyloid plaque, but offers little guidance on how to do that or when the drug may need to be restarted.
Key Takeaways
-
The FDA approved Lilly’s donanemab with labeling that states providers may consider stopping dosing based on a reduction of amyloid plaques to minimal levels in PET imaging.
“Consider stopping dosing with Kisunla based on reduction of amyloid plaques to minimal levels on amyloid PET imaging,” labeling...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?